Insulet Corporation – NASDAQ:PODD
Insulet stock price today
$327.75
+62.62
+23.62%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Insulet stock price monthly change
+31.26%
month
Insulet stock price quarterly change
+31.26%
quarter
Insulet stock price yearly change
+19.74%
year
Insulet key metrics
Market Cap | 18.28B |
Enterprise value | 22.51B |
P/E | 5233.33 |
EV/Sales | 17.24 |
EV/EBITDA | 225.78 |
Price/Sales | 16.68 |
Price/Book | 45.72 |
PEG ratio | -73.09 |
EPS | 3.35 |
Revenue | 1.78B |
EBITDA | 192.3M |
Income | 234M |
Revenue Q/Q | 23.34% |
Revenue Y/Y | 30.16% |
Profit margin | 0.35% |
Oper. margin | 2.88% |
Gross margin | 61.72% |
EBIT margin | 2.88% |
EBITDA margin | 10.8% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInsulet stock price history
Insulet stock forecast
Insulet financial statements
Average Price Target
$261
Potential downside: -20.36%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 396.5M | 27.3M | 6.89% |
|---|---|---|---|
| Sep 2023 | 432.7M | 51.9M | 11.99% |
| Dec 2023 | 509.8M | 103.3M | 20.26% |
| Mar 2024 | 441.7M | 51.5M | 11.66% |
| 2024-02-22 | 0.66 | 1.4 |
|---|
| Jun 2023 | 2385800000 | 1.83B | 76.78% |
|---|---|---|---|
| Sep 2023 | 2467700000 | 1.86B | 75.38% |
| Dec 2023 | 2588200000 | 1.85B | 71.69% |
| Mar 2024 | 2624000000 | 1.83B | 69.87% |
| Jun 2023 | 44M | -23.1M | 3.2M |
|---|---|---|---|
| Sep 2023 | 56M | -22.6M | -6.9M |
| Dec 2023 | 44.9M | -31.6M | 2.2M |
| Mar 2024 | 87.6M | -24M | -14.1M |
Insulet alternative data
| Aug 2023 | 2,600 |
|---|---|
| Sep 2023 | 2,600 |
| Oct 2023 | 2,600 |
| Nov 2023 | 2,600 |
| Dec 2023 | 2,600 |
| Jan 2024 | 2,600 |
| Feb 2024 | 2,600 |
| Mar 2024 | 3,000 |
| Apr 2024 | 3,000 |
| May 2024 | 3,000 |
| Jun 2024 | 3,000 |
| Jul 2024 | 3,000 |
Insulet other data
100.00%
0.00%
of PODD is owned by hedge funds
457
-4
70.59M
+537.58K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 11609 |
| May 2024 | 0 | 3300 |
| Jun 2024 | 0 | 10991 |
| Aug 2024 | 100 | 3211 |
| Sep 2024 | 0 | 15517 |
| Nov 2024 | 0 | 508 |
| Dec 2024 | 0 | 5277 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BENJAMIN ERIC officer: EVP, CPXPO | Common Stock | 4,362 | $267.6 | $1,167,271 | ||
Sale | BUDDEN LAUREN officer: Group VP, CAO and Cont.. | Common Stock | 915 | $275.62 | $252,192 | ||
Sale | BORIO LUCIANA director | Common Stock | 508 | $274.8 | $139,598 | ||
Option | HOPFIELD JESSICA director | Common Stock | 7,628 | $29.87 | $227,848 | ||
Sale | HOPFIELD JESSICA director | Common Stock | 7,628 | $225.26 | $1,718,283 | ||
Option | HOPFIELD JESSICA director | Stock Option (Right to Buy) | 7,628 | $29.87 | $227,848 | ||
Sale | SCANNELL TIMOTHY J director | Common Stock | 5,000 | $225.84 | $1,129,200 | ||
Sale | FIELD MARK N officer: SVP & Chief Technology.. | Common Stock | 1,383 | $220.87 | $305,463 | ||
Sale | BUDDEN LAUREN officer: Group VP, CAO and Cont.. | Common Stock | 1,506 | $221.41 | $333,443 | ||
Sale | SINGH PREM officer: SVP, Global Operations | Common Stock | 1,824 | $202.27 | $368,940 |
| Patent |
|---|
Grant Filling date: 1 Dec 2021 Issue date: 13 Sep 2022 |
Grant Utility: Variable fill drug delivery device Filling date: 29 Jul 2019 Issue date: 13 Sep 2022 |
Application Filling date: 2 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 10 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 10 Feb 2022 Issue date: 1 Sep 2022 |
Application INTEGRATION OF SENSORS FOR DRUG DELIVERY COMPENSATION IN AUTOMATED MEDICATION DELIVERY (AMD) SYSTEMS Filling date: 9 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 4 Feb 2022 Issue date: 11 Aug 2022 |
Application SYSTEMS AND METHODS FOR INCORPORATING CO-FORMULATIONS OF INSULIN IN AN AUTOMATIC INSULIN DELIVERY SYSTEM Filling date: 24 Jan 2022 Issue date: 4 Aug 2022 |
Application Filling date: 24 Jan 2022 Issue date: 4 Aug 2022 |
Application Filling date: 19 Jan 2022 Issue date: 4 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
DexCom: Attractive Discount After Strong Earnings Results
8 Tax-Loss Sell Alerts For December
Insulet Corporation: Still No Bargain
Insulet: Losing More Weight
Insulet: The Game-Changer In Diabetes Management
Insulet: Enthusiasm Might Be Too High
Diabetes Deep-Dive With DexCom And Embecta: Polar Opposite Diabetes Plays
Insulet: Omnipod 5 Driving Revenue - But Expenses Elevated
-
What's the price of Insulet stock today?
One share of Insulet stock can currently be purchased for approximately $327.75.
-
When is Insulet's next earnings date?
Unfortunately, Insulet's (PODD) next earnings date is currently unknown.
-
Does Insulet pay dividends?
No, Insulet does not pay dividends.
-
How much money does Insulet make?
Insulet has a market capitalization of 18.28B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 30.02% to 1.7B US dollars. Insulet earned 206.3M US dollars in net income (profit) last year or $1.4 on an earnings per share basis.
-
What is Insulet's stock symbol?
Insulet Corporation is traded on the NASDAQ under the ticker symbol "PODD".
-
What is Insulet's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Insulet?
Shares of Insulet can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Insulet's key executives?
Insulet's management team includes the following people:
- Ms. Shacey Petrovic Pres, Chief Executive Officer & Director(age: 51, pay: $1,800,000)
- Mr. Charles Alpuche Executive Vice President & Chief Operating Officer(age: 65, pay: $1,050,000)
- Mr. Wayde D. McMillan Executive Vice President,Chief Financial Officer & Treasurer(age: 55, pay: $969,460)
- Mr. Bret Christensen Executive Vice President & Chief Commercial Officer(age: 54, pay: $918,470)
- Mr. Dan Manea Senior Vice President & Chief HR Officer(age: 58, pay: $841,640)
-
How many employees does Insulet have?
As Jul 2024, Insulet employs 3,000 workers.
-
When Insulet went public?
Insulet Corporation is publicly traded company for more then 18 years since IPO on 15 May 2007.
-
What is Insulet's official website?
The official website for Insulet is insulet.com.
-
Where are Insulet's headquarters?
Insulet is headquartered at 100 Nagog Park, Acton, MA.
-
How can i contact Insulet?
Insulet's mailing address is 100 Nagog Park, Acton, MA and company can be reached via phone at 978 600 7000.
-
What is Insulet stock forecast & price target?
Based on 6 Wall Street analysts` predicted price targets for Insulet in the last 12 months, the avarage price target is $261. The average price target represents a -20.36% change from the last price of $327.75.
Insulet company profile:
Insulet Corporation
insulet.comExchange:
NASDAQ
Full time employees:
3,000
Industry:
Medical - Devices
Sector:
Healthcare
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
100 Nagog Park
Acton, MA 01720
Acton, MA 01720
CIK: 0001145197
ISIN: US45784P1012
CUSIP: 45784P101
